BCL2 and cancer: Formononetin was reported to directly modulate the expressions of both antiapoptotic and proapoptotic members of Bcl-2 family in many cancer cells, including colon (Huang et al., 2015), nasopharyngeal (Qi et al., 2016), prostate (Ye et al., 2012; Huang et al., 2014; Liu et al., 2014a; Zhang et al., 2014), and breast cancer cells (Zhang et al., 2018a).